We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Treatment of Anemia in Patients With Cancer Who Are Not Currently Receiving Chemotherapy or Radiotherapy

This study has been terminated.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00083486
First Posted: May 27, 2004
Last Update Posted: April 27, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
  Purpose
The purpose of this study is to determine the effectiveness of different doses of epoetin alfa for treating anemia in patients who have cancer; or patients who no longer have any signs of cancer, but remain anemic as a result of their treatment. These patients should not be currently receiving chemotherapy or radiotherapy. A subject's participation in the study will last approximately 6 months. Subjects will receive weekly doses of epoetin alfa or placebo. Their hemoglobin will be tested every week.

Condition Intervention Phase
Anemia Drug: epoetin alfa Phase 3

Study Type: Interventional
Study Design: Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.:

Study Start Date: February 2004
Study Completion Date: October 2004
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Body weight >/=99 lbs
  • ECOG 0-2
  • Anemia results from cancer, chemotherapy, radiotherapy or an association with hormonal therapy or immunotherapy
  • Screening hemoglobin level of </=11.0 g/dL for men or </=10.0 for women
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00083486


Locations
United States, Arkansas
Heritage Physician Group-Oncology
Hot Springs, Arkansas, United States, 71913
United States, Georgia
Spalding Oncology Services
Griffin, Georgia, United States, 30224
United States, Illinois
Southern Illinois Hematology
Centralia, Illinois, United States, 62801
United States, Maryland
BioLab Research
Rockville, Maryland, United States, 20852
United States, New York
Slocum-Dickson Medical Group, PC
New Hartford, New York, United States, 13413
United States, North Carolina
NorthEast Urology Research
Concord, North Carolina, United States
United States, Ohio
Mid Ohio Oncology Hematology
Columbus, Ohio, United States, 43213
United States, Pennsylvania
Drexel University College of Medicine
Philadelphia, Pennsylvania, United States, 19102
United States, South Carolina
Caroline Cancer Center
Aiken, South Carolina, United States, 29403
Charleston Hematology Oncology
Charleston, South Carolina, United States, 29403
Charleston Cancer Care
Charleston, South Carolina, United States, 29406
United States, Tennessee
Volunteer Research Group
Knoxville, Tennessee, United States, 37920
Sponsors and Collaborators
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
  More Information

ClinicalTrials.gov Identifier: NCT00083486     History of Changes
Other Study ID Numbers: CR010939
EPO-CAN-203
First Submitted: May 24, 2004
First Posted: May 27, 2004
Last Update Posted: April 27, 2011
Last Verified: April 2011

Additional relevant MeSH terms:
Anemia
Hematologic Diseases
Epoetin Alfa
Hematinics